P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model

Toshiro Shirakawa, Akinobu Gotoh, Thomas Gardner, Chinghai Kao, Zhu Jun Zhang, Shigeji Matsubara, Yoshitaka Wada, Nobuyuki Hinata, Masato Fujisawa, Keisuke Hanioka, Masafumi Matsuo, Sadao Kamidono

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Benign prostatic hyperplasia (BPH) is the most common proliferative disease affecting men. Numerous minimally invasive technologies are being developed or are currently in use to obviate the need for transurethral surgery. The goal of the present study was to develop a novel molecular based approach for the treatment of BPH using recombinant p53 adenoviral vector. The over-expression of wt-p53 can cause cell apoptosis or cell growth arrest, thus preventing the uncontrolled cell proliferation underlying BPH pathophysiology. Methods Ad-CMV-p53, a replication-deficient recombinant adenovirus containing cytomegalovirus promoter driving p53 gene, was used. Human prostate stromal (PS) cells were evaluated for apoptosis (TUNEL assay), mRNA levels of key cell cycle regulators influencing apoptosis (p-53, Bax and Bcl-2) using quantitative RT-PCR and cytotoxicity after Ad-CMV-p53. AdCMV-p53 was unilaterally injected into rat ventral prostates and growth inhibition was measured by prostate weight 3 weeks after injection. Results In vitro exposure to Ad-CMV-p53 significantly inhibited the proliferation of PS cells, induced mRNA over-expression of both wt-p53 and Bax, and increased the proportion of apoptotic cells. A 30% decrease in average prostate weight was demonstrated in rodents after Ad-CMV-p53 injection. Conclusions The results suggest that further investigation of molecular gene therapy with recombinant wt-p53 adenovirus for the treatment of BPH is warranted.

Original languageEnglish
Pages (from-to)426-432
Number of pages7
JournalJournal of Gene Medicine
Volume2
Issue number6
StatePublished - Nov 2000

Fingerprint

Prostatic Hyperplasia
Prostate
Theoretical Models
Growth
Apoptosis
Stromal Cells
Adenoviridae
Weights and Measures
Messenger RNA
Injections
p53 Genes
In Situ Nick-End Labeling
Cytomegalovirus
Genetic Therapy
Rodentia
Cell Cycle
Cell Proliferation
Technology
Polymerase Chain Reaction
Therapeutics

Keywords

  • Adenovirus
  • Benign prostatic hyperplasia (BPH)
  • Gene therapy
  • p53

ASJC Scopus subject areas

  • Genetics

Cite this

P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. / Shirakawa, Toshiro; Gotoh, Akinobu; Gardner, Thomas; Kao, Chinghai; Zhang, Zhu Jun; Matsubara, Shigeji; Wada, Yoshitaka; Hinata, Nobuyuki; Fujisawa, Masato; Hanioka, Keisuke; Matsuo, Masafumi; Kamidono, Sadao.

In: Journal of Gene Medicine, Vol. 2, No. 6, 11.2000, p. 426-432.

Research output: Contribution to journalArticle

Shirakawa, T, Gotoh, A, Gardner, T, Kao, C, Zhang, ZJ, Matsubara, S, Wada, Y, Hinata, N, Fujisawa, M, Hanioka, K, Matsuo, M & Kamidono, S 2000, 'P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model', Journal of Gene Medicine, vol. 2, no. 6, pp. 426-432.
Shirakawa, Toshiro ; Gotoh, Akinobu ; Gardner, Thomas ; Kao, Chinghai ; Zhang, Zhu Jun ; Matsubara, Shigeji ; Wada, Yoshitaka ; Hinata, Nobuyuki ; Fujisawa, Masato ; Hanioka, Keisuke ; Matsuo, Masafumi ; Kamidono, Sadao. / P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. In: Journal of Gene Medicine. 2000 ; Vol. 2, No. 6. pp. 426-432.
@article{de523ee37af84eb38d88659f978f523c,
title = "P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model",
abstract = "Background Benign prostatic hyperplasia (BPH) is the most common proliferative disease affecting men. Numerous minimally invasive technologies are being developed or are currently in use to obviate the need for transurethral surgery. The goal of the present study was to develop a novel molecular based approach for the treatment of BPH using recombinant p53 adenoviral vector. The over-expression of wt-p53 can cause cell apoptosis or cell growth arrest, thus preventing the uncontrolled cell proliferation underlying BPH pathophysiology. Methods Ad-CMV-p53, a replication-deficient recombinant adenovirus containing cytomegalovirus promoter driving p53 gene, was used. Human prostate stromal (PS) cells were evaluated for apoptosis (TUNEL assay), mRNA levels of key cell cycle regulators influencing apoptosis (p-53, Bax and Bcl-2) using quantitative RT-PCR and cytotoxicity after Ad-CMV-p53. AdCMV-p53 was unilaterally injected into rat ventral prostates and growth inhibition was measured by prostate weight 3 weeks after injection. Results In vitro exposure to Ad-CMV-p53 significantly inhibited the proliferation of PS cells, induced mRNA over-expression of both wt-p53 and Bax, and increased the proportion of apoptotic cells. A 30{\%} decrease in average prostate weight was demonstrated in rodents after Ad-CMV-p53 injection. Conclusions The results suggest that further investigation of molecular gene therapy with recombinant wt-p53 adenovirus for the treatment of BPH is warranted.",
keywords = "Adenovirus, Benign prostatic hyperplasia (BPH), Gene therapy, p53",
author = "Toshiro Shirakawa and Akinobu Gotoh and Thomas Gardner and Chinghai Kao and Zhang, {Zhu Jun} and Shigeji Matsubara and Yoshitaka Wada and Nobuyuki Hinata and Masato Fujisawa and Keisuke Hanioka and Masafumi Matsuo and Sadao Kamidono",
year = "2000",
month = "11",
language = "English",
volume = "2",
pages = "426--432",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - P53 Adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model

AU - Shirakawa, Toshiro

AU - Gotoh, Akinobu

AU - Gardner, Thomas

AU - Kao, Chinghai

AU - Zhang, Zhu Jun

AU - Matsubara, Shigeji

AU - Wada, Yoshitaka

AU - Hinata, Nobuyuki

AU - Fujisawa, Masato

AU - Hanioka, Keisuke

AU - Matsuo, Masafumi

AU - Kamidono, Sadao

PY - 2000/11

Y1 - 2000/11

N2 - Background Benign prostatic hyperplasia (BPH) is the most common proliferative disease affecting men. Numerous minimally invasive technologies are being developed or are currently in use to obviate the need for transurethral surgery. The goal of the present study was to develop a novel molecular based approach for the treatment of BPH using recombinant p53 adenoviral vector. The over-expression of wt-p53 can cause cell apoptosis or cell growth arrest, thus preventing the uncontrolled cell proliferation underlying BPH pathophysiology. Methods Ad-CMV-p53, a replication-deficient recombinant adenovirus containing cytomegalovirus promoter driving p53 gene, was used. Human prostate stromal (PS) cells were evaluated for apoptosis (TUNEL assay), mRNA levels of key cell cycle regulators influencing apoptosis (p-53, Bax and Bcl-2) using quantitative RT-PCR and cytotoxicity after Ad-CMV-p53. AdCMV-p53 was unilaterally injected into rat ventral prostates and growth inhibition was measured by prostate weight 3 weeks after injection. Results In vitro exposure to Ad-CMV-p53 significantly inhibited the proliferation of PS cells, induced mRNA over-expression of both wt-p53 and Bax, and increased the proportion of apoptotic cells. A 30% decrease in average prostate weight was demonstrated in rodents after Ad-CMV-p53 injection. Conclusions The results suggest that further investigation of molecular gene therapy with recombinant wt-p53 adenovirus for the treatment of BPH is warranted.

AB - Background Benign prostatic hyperplasia (BPH) is the most common proliferative disease affecting men. Numerous minimally invasive technologies are being developed or are currently in use to obviate the need for transurethral surgery. The goal of the present study was to develop a novel molecular based approach for the treatment of BPH using recombinant p53 adenoviral vector. The over-expression of wt-p53 can cause cell apoptosis or cell growth arrest, thus preventing the uncontrolled cell proliferation underlying BPH pathophysiology. Methods Ad-CMV-p53, a replication-deficient recombinant adenovirus containing cytomegalovirus promoter driving p53 gene, was used. Human prostate stromal (PS) cells were evaluated for apoptosis (TUNEL assay), mRNA levels of key cell cycle regulators influencing apoptosis (p-53, Bax and Bcl-2) using quantitative RT-PCR and cytotoxicity after Ad-CMV-p53. AdCMV-p53 was unilaterally injected into rat ventral prostates and growth inhibition was measured by prostate weight 3 weeks after injection. Results In vitro exposure to Ad-CMV-p53 significantly inhibited the proliferation of PS cells, induced mRNA over-expression of both wt-p53 and Bax, and increased the proportion of apoptotic cells. A 30% decrease in average prostate weight was demonstrated in rodents after Ad-CMV-p53 injection. Conclusions The results suggest that further investigation of molecular gene therapy with recombinant wt-p53 adenovirus for the treatment of BPH is warranted.

KW - Adenovirus

KW - Benign prostatic hyperplasia (BPH)

KW - Gene therapy

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0034330253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034330253&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 426

EP - 432

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 6

ER -